Vitamin D Metabolites as Biomarkers for the Identification of Kidney Injury in Cardiac Surgery

The investigators will be measuring vitamin D metabolites in blood samples drawn from patients undergoing cardiac surgery to determine the correlation with renal function as assessed by serum creatinine. The investigators will include 20 patients in each of the following 3 groups based on serum creatinine measured within 28-days of surgery: 1) normal kidney function (eGFR > 60 mL/min, n=20), 2) moderate impaired kidney function, eGFR between 30 and 60 mL/min (n=20) and 3) severe kidney dysfunction eGFR < 30 mL/min (n=20).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Acute Kidney Injuries Acute Kidney Injury Chronic Disease Chronic Renal Diseases Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Health Network-Toronto General Hospital

Toronto, Ontario, M5G 2C4, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

≥ 18 years
Patients undergoing cardiac surgery
Serum Creatinine measured with 28 days of surgery

Exclusion criteria

Exogeneous calcitriol (1,25(OH)2D3) intake
History of parathyroidectomy
Patients with liver or kidney cancer
Patients with liver disease (e.g. liver failure, cirrhosis)

Treatment and study plan

Primary outcomes

Determine the correlation between eGFR as determined serum creatinine and vitamin D metabolites as markers of kidney function

Time frame: Up to 1 month before surgery up until POD 7

serum creatinine (sCr) and vitamin D metabolites (specifically 25(OH)D3 and 1,25(OH)2D3) will be measured in the same blood sample to determine the incidence of AKI and CKD in patients undergoing cardiac surgery

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

University of Toronto

Registry information

Acronym: VITAL

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Nov 14, 2024
Registry last updated: Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting